References
- Matthews S J, McCoy C. Thalidomide: a review of approved and investigational uses. Clin Therap 2003; 25: 342–395
- Yaccoby S, Johnson C L, Mahaffey S C, Wezeman M J, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002; 100: 4162–4168
- Hideshima T, Chauhan D, Shima Y, Raje N, Davies F E, Tai Y T, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950
- Richardson P G, Schlossman R L, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067
- Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530
- Johnston R E, Abdalla S H. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymph 2002; 43: 351–354
- Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002; 16: 1–6
- Steins M B, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834–839
- Dalle J H, Leblond P, Decouvelaere A, Yakoub-Agha I, Preudhomme C, Nelken B, et al. Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL. Leukemia 2003; 17: 2056–2057
- Merup M, Kutti J, Birgergard G, Mauritzson N, Bjorkholm M, Markevarn B, et al. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002; 19: 79–86
- Styczynski J, Wysocki M, Balwierz W, Kowalczyk J R. Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin. Leukemia 2002; 16: 820–825
- Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99: 4079–4086
- Munshi N C, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103: 1799–1806
- Miyachi H, Azuma A, Hioki E, Iwasaki S, Kobayashi Y, Hashimoto Y. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Bioch Bioph Res Com 1996; 224: 426–430
- El-Obeid A, Sunnuqrut N, Hussain A, Al-Hussein K, Gutierrez M I, Bhatia K. Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Leukemia Res 2004; 28: 133–137